Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.

JAMA oncology - 1 Oct 2015

Desmond Andrea, Kurian Allison W, Gabree Michele, Mills Meredith A, Anderson Michael J, Kobayashi Yuya, Horick Nora, Yang Shan, Shannon Kristen M, Tung Nadine, Ford James M, Lincoln Stephen E, Ellisen Leif W

Abstract excerpt

IMPORTANCE: The practice of genetic testing for hereditary breast and/or ovarian cancer (HBOC) is rapidly evolving owing to the recent introduction of multigene panels. While these tests may identify 40% to 50% more individuals with hereditary cancer gene mutations than does testing for BRCA1/2 alone, whether finding such mutations will alter clinical management is unknown. OBJECTIVE: To define the potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Academic Medical Centers
Share to Boston

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to California

Share to Genetic Counseling

Share to Heredity

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 26270727
DOI: 10.1001/jamaoncol.2015.2690

Genes

BRCA1
ATM
CHEK2
PALB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.PMID 26270727Read ↗

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?Semantic proximity Read ↗

Effects of Cancer Genetic Panel Testing on at-Risk Individuals.Semantic proximity Read ↗

Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findingsSemantic proximity Read ↗

Initial Results of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer and Lynch Syndrome.Semantic proximity Read ↗

Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.Semantic proximity Read ↗

Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working GroupSemantic proximity Read ↗

Breast cancer multigene germline panel testing in mainstream oncology based on clinical-public health utility (cancer mortality benefit): ESMO Precision Oncology Working Group recommendationsSemantic proximity Read ↗

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.Semantic proximity Read ↗

Outcomes of retesting BRCA negative patients using multigene panels.Semantic proximity Read ↗

Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.Semantic proximity Read ↗

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.Semantic proximity Read ↗

Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.